Posts Tagged ‘Cirrosi’

Categories

Posted in:

Monday July 30th, 2018

Statins efficacy confirmed in advanced phases of cirrhosis in an animal model

Researchers from IDIBAPS publish a translational paper in Gastroenterology demonstrating that statins improve survival and main clinical symptoms in advanced cirrhosis and acute-on-chronic liver failure (ACLF). The paper also describes and validates the first animal model of ACLF, which has allowed studying the beneficial effects of statins. The work has been coordinated by Jordi Gracia-Sancho, leader of the Liver Vascular Biology Research Group from IDIBAPS and CIBEREHD, and Jaume Bosch, emeritus investigator from the same group, and first authors are Dinesh Tripathi and Marina Vilaseca. Read the rest of this entry »

Comments Closed
Monday January 16th, 2017

Hospital Clinic-IDIBAPS leads a European project to fight against cirrhosis within the Horizon 2020 program

Hospital Clínic-IDIBAPS is leading a European project to evaluate the efficacy of treatment with the combination of rifaximin, an antibiotic that modulates the intestinal microbiome, and statins in patients with advanced cirrhosis. The project, called LIVERHOPE, will also focuse on the search for biomarkers of the disease. LIVERHOPE is coordinated by Dr. Pere Ginès, head of the Hepatology Department of the Hospital Clínic and of the team of Mechanisms of liver diseases and complications of cirrhosis of IDIBAPS, and a total of 16 institutions are participating among clinical centers, universities and European companies. This project is part of the Horizon 2020 European research and innovation framework program and it is endowed with a budget of 6 million euros.

Read the rest of this entry »

Comments Closed
Thursday November 24th, 2016

Simvastatin can lengthen the survival of patients with cirrhosis

Gastroenterology has published a clinical trial promoted and coordinated by Hospital Clínic – IDIBAPS where it is shown that the addition of simvastatin to standard therapy in patients with cirrhosis can lengthen their survival. The article is signed by, among others, Dr. Jaume Bosch, hepatologist at Clínic and head of the research team Liver hemodynamics and portal hypertension of IDIBAPS; Dr. Juan Carlos García-Pagán and Juan González-Abraldes, from the same research group, and Dr. Fernando Torres, director of the IDIBAPS medical statistics platform. Read the rest of this entry »

Comments Closed

Categories

Posted in:

Friday December 11th, 2015

Scientists in Barcelona discover a potential treatment for cirrhosis

Scientists headed by Raúl Méndez, ICREA research professor at the Institute for Research in Biomedicine (IRB Barcelona), and Mercedes Fernández, at IDIBAPS in Barcelona, reveal that the inhibition of CPEB4 protein may prevent the development of the abnormal blood vessels associated with cirrhosis. Pathological angiogenesis is one of the most serious complications in patients with cirrhosis and a key factor in the development and worsening of the disease. Consequently, many research efforts focus on identifying treatments for this condition. The results of the study have been published in the most recent issue of Gastroenterology.

Read the rest of this entry »

Comments Closed
Monday January 12th, 2015

The induction of the transcription factor KLF2 improves liver cirrhosis and portal hypertension

A study led by researchers from IDIBAPS shows, for the first time, that the induction in the liver of the transcription factor called KLF2 (Kruppel-like factor 2), a protein that promotes the expression of vasoprotective genes, significantly improves liver cirrhosis and portal hypertension. Dr. Jordi Gracia-Sancho, Ramón y Cajal researcher at the IDIBAPS group Liver hemodynamics and portal hypertension: Digestive bleeding secondary to ruptured esophageal varicose veins, and Dr. Jaume Bosch, director of the same team, have led this study published in the Gut journal whose first authorship share Giusi Marrone and Raquel Maeso-Díaz. This research was conducted in collaboration with a team from the Harvard Medical School & Brigham and Women’s Hospital.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Thursday January 26th, 2012

The last IDIBAPS seminar focused on the advancement in cirrhosis classification

Dra. Guadalupe García-Tsao i Dr. Jaume Bosch a l'IDIBAPS
The diagnosis of cirrhosis has experienced important progresses in recent years. In addition to improved techniques for a good diagnose, this diagnosis is now richer in information about patient’s prognosis and the degree of development of pathology. Dr. Guadalupe Garcia-Tsao, from Yale University, spoke about it at a recent IDIBAPS seminar, held on Monday January 23. She is a regular collaborator of the team led by Dr. Jaume Bosch at IDIBAPS – Hospital Clínic, an international reference in the field of hepatology and liver hemodynamics.

Read the rest of this entry »

Comments Closed